Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for NextCure, Inc. (NXTC : NSDQ)
 
 • Company Description   
NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland.

Number of Employees: 87

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.64 Daily Weekly Monthly
20 Day Moving Average: 148,545 shares
Shares Outstanding: 27.75 (millions)
Market Capitalization: $101.00 (millions)
Beta: 0.15
52 Week High: $9.18
52 Week Low: $3.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.04% -13.32%
12 Week -27.20% -19.96%
Year To Date -39.33% -25.87%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9000 VIRGINIA MANOR ROAD SUITE 200
-
BELTSVILLE,MD 20705
USA
ph: 240-399-4900
fax: -
ir@nextcure.com http://www.nextcure.com
 
 • General Corporate Information   
Officers
Michael Richman - President; Chief Executive Officer and Director
David Kabakoff - Chairman of the Board
Steven P. Cobourn - Chief Financial Officer
Anne Borgman - Director
Ellen G. Feigal - Director

Peer Information
NextCure, Inc. (CORR.)
NextCure, Inc. (RSPI)
NextCure, Inc. (CGXP)
NextCure, Inc. (BGEN)
NextCure, Inc. (GTBP)
NextCure, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 65343E108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 27.75
Most Recent Split Date: (:1)
Beta: 0.15
Market Capitalization: $101.00 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.73 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.68 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.47
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -23.33%
vs. Previous Quarter: -21.31%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -30.64
12/31/21 - -27.09
09/30/21 - -25.04
ROA
03/31/22 - -29.43
12/31/21 - -26.02
09/30/21 - -24.02
Current Ratio
03/31/22 - 32.52
12/31/21 - 34.48
09/30/21 - 32.95
Quick Ratio
03/31/22 - -
12/31/21 - 34.48
09/30/21 - 32.95
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 7.71
12/31/21 - 8.45
09/30/21 - 8.99
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©